$1.45
-0.03[-2.03%]
At close: Apr 19
$1.45
0[0.00%]
After Hours: 8:19AM EDT
Molecular Templates
(NASDAQ:MTEM)Latest News for Molecular Templates Stock (NASDAQ:MTEM)
Molecular Templates Stock (NASDAQ: MTEM)
Categories: All
Friday, April 12, 2024
- Molecular Templates Inc Estimates That It Will Incur Aggregate Pre-Tax Charges Of ~$0.1M In Connection With Reduction In Force; Effective April 30; Reduction To Extend Resources To Allow Co To Continue To Support Clinical Studies For MT-6402, MT-8421 And MT-0169Benzinga Newsdesk - Apr 12, 2024, 4:26PM
- Molecular Templates Inc Says Reduction In Force Would Reduce Company's Current Workforce By ~30%; Approved A Reduction In Force; Expects That Reduction In Force Will Be Complete By End Of April 2024Benzinga Newsdesk - Apr 12, 2024, 4:25PM
Tuesday, April 09, 2024
- 12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga Insights - Apr 9, 2024, 4:31PM
- What's Going On With Molecular Templates Stock?Erica Kollmann - Apr 9, 2024, 12:37PM
- Molecular Templates shares are trading higher after the company announced that it will present interim data from its MT-6402 Phase I study in patients with PD-L1+ solid tumors at the 2024 AACR annual meeting.Benzinga Newsdesk - Apr 9, 2024, 8:29AM
- Molecular Templates Presents Interim Data From MT-6402 Phase I Study In Patients With PD-L1+ Solid Tumors At 2024 AACR Annual MeetingBenzinga Newsdesk - Apr 9, 2024, 8:27AM
Friday, April 05, 2024
Thursday, March 28, 2024
- Molecular Templates shares are trading higher after the company announced a $9.5 million private placement offering.Benzinga Newsdesk - Mar 28, 2024, 9:21AM
- Molecular Templates Announces $9.5M Private Placement Offering And Agreement To Amend Second Tranche Of July 2023 Purchase AgreementBenzinga Newsdesk - Mar 28, 2024, 8:11AM
Monday, March 25, 2024
Tuesday, March 19, 2024
Monday, March 18, 2024
Friday, March 15, 2024
Monday, November 13, 2023
Friday, November 10, 2023
Thursday, November 02, 2023
- Molecular Templates Announces First Patient Dosed In Phase 1 Trial Evaluating MT-8421, A Novel Engineered Toxin Body Targeting CTLA-4, In Advanced Solid TumorsBenzinga Newsdesk - Nov 2, 2023, 5:28PM
- Molecular Templates Chief Medical Officer Awarded $76K Worth of Stock OptionsBenzinga Insights - Nov 2, 2023, 11:01AM
Wednesday, November 01, 2023
- Molecular Templates Board Member Awarded $6K Worth of Stock OptionsBenzinga Insights - Nov 1, 2023, 11:00AM
- Board Member at Molecular Templates Acquires Company Stock Options Worth 1,000 SharesBenzinga Insights - Nov 1, 2023, 11:00AM
- Molecular Templates Director Awarded $6K Worth of Stock OptionsBenzinga Insights - Nov 1, 2023, 11:00AM
- Director at Molecular Templates Acquires Company Stock Options Worth 1,000 SharesBenzinga Insights - Nov 1, 2023, 11:00AM
Thursday, August 31, 2023
Friday, August 11, 2023
Thursday, August 10, 2023
Wednesday, August 02, 2023
Thursday, July 20, 2023
Thursday, July 13, 2023
Thursday, June 01, 2023
Tuesday, May 16, 2023
Monday, April 03, 2023
Friday, March 31, 2023
Friday, March 24, 2023
Monday, March 13, 2023
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga Insights - Mar 13, 2023, 1:31PM
- Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day SessionLisa Levin - Mar 13, 2023, 1:22PM
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Mar 13, 2023, 9:06AM
- Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving PremarketLisa Levin - Mar 13, 2023, 8:19AM
Friday, March 10, 2023
- Why JAKKS Pacific Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Friday's Mid-Day SessionLisa Levin - Mar 10, 2023, 12:58PM
- Nasdaq Down 50 Points; PlayAGS Shares Spike HigherLisa Levin - Mar 10, 2023, 12:03PM
- 12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga Insights - Mar 10, 2023, 8:06AM
Thursday, March 09, 2023
- Molecular Templates shares are trading higher after the company received FDA clearance to proceed for clinical testing of its novel MT-8421 ETB program.Michael Horton - Mar 9, 2023, 10:57AM
- Molecular Templates Announces IND Acceptance By FDA For MT-8421 ETB Program Targeting CTLA-4Benzinga Newsdesk - Mar 9, 2023, 10:03AM